- GlobeNewswire•8 days agoBasilea expands oncology drug candidate BAL101553 clinical phase 1/2a oral study to include glioblastoma patients
Basel, Switzerland, December 02, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the expansion of its ongoing oncology drug candidate BAL101553 clinical phase 1/2a oral formulation study. ...
- GlobeNewswire•3 months agoBasilea announces distribution agreement with Unimedic for CRESEMBA® (isavuconazole) and Zevtera® (ceftobiprole) in the Nordic countries
Basel, Switzerland, September 20, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license and distribution agreement ...
- GlobeNewswire•3 months ago
Basilea grants Asahi Kasei Pharma exclusive license to develop and commercialize isavuconazole in Japan Basilea eligible for upfront and milestone payments of up to CHF 67 million and double-digit royalties ...
PK5.BE : Summary for BASILEA PHARM.NA SF 1 - Yahoo Finance
BASILEA PHARM.NA SF 1 (PK5.BE)
Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
At close: 2:08 AM EST
|Bid||64.78 x 9000|
|Ask||65.50 x 9000|
|Day's Range||65.20 - 65.20|
|52 Week Range||63.24 - 70.50|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|